Pratap Devarapalli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pratap Devarapalli has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ranjith Kumavath
Department of Biotechnology, School of Life Sciences, Pondicherry University, Puducherry, India
3 shared publications - Mohammad Yunus Ansari
Department of Biomedical Sciences College of Medicine, Northeast Ohio Medical University Rootstown Ohio USA
2 shared publications - Nazir M. Khan
Department of Orthopaedics, Emory University
2 shared publications - Nishad Deshpande
Department of Informatics, CSIR Unit for Research and Development of Information Products, Pune, Maharashtra, India
2 shared publications Rajkumar Hirwani
2 shared publicationsSara Haynie
Department of Anatomy & Neurobiology, Northeast Ohio Medical University, 4209 St Rt 44, Rootstown, OH 44272, USA
2 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Patents in the AI Era: Challenges at the Intersection of AI Inventions and Australian Patent Law
Patenting AI inventions presents challenges due to the complex intersection of human-centric patent law and inventions that involve non-human ingenuity. This article critically examines the central research question: Can Australia's traditional patent law framework, designed for human inventors, adequately address the unique challenges posed by AI-generated and AI-assisted inventions, and what reforms are necessary to reconcile this technological disruption? Through doctrinal analysis of judicial precedents, including the landmark Thaler v Commissioner of Patents (2021-2022) litigation, and statutory interpretation of the Patents Act 1990 (Cth), this study identifies systemic tensions between AI-driven innovation and Australia's human-centric patentability criteria. The analysis focuses on four key challenges: (1) the ambiguity of 'manner of manufacture' requirements for AI inventions lacking direct technical contributions to computing; (2) novel complexities in assessing the prior art and non-obviousness given AI's access to vast, opaque datasets; (3) the inadequacy of the 'person skilled in the art' standard for evaluating AI's inventive step; and (4) policy risks associated with lenient utility thresholds in an era of AI's prolific output. By critically analysing existing laws and precedents, the article contends that Australia's current patent regime is insufficient to address AI-driven inventions. It identifies that the human-centric nature of patent law should be preserved and proposes reforms to the Patents Act 1990 (Cth) to ensure that AI inventions are adequately captured under the patentability criteria, as well as procedural reforms to incorporate a multidisciplinary review process for evaluating technical advancements across disparate fields.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPatents in the AI Era: Challenges at the Intersection of AI Inventions and Australian Patent Law
Patenting AI inventions presents challenges due to the complex intersection of human-centric patent law and inventions that involve non-human ingenuity. This article critically examines the central research question: Can Australia's traditional patent law framework, designed for human inventors, adequately address the unique challenges posed by AI-generated and AI-assisted inventions, and what reforms are necessary to reconcile this technological disruption? Through doctrinal analysis of judicial precedents, including the landmark Thaler v Commissioner of Patents (2021-2022) litigation, and statutory interpretation of the Patents Act 1990 (Cth), this study identifies systemic tensions between AI-driven innovation and Australia's human-centric patentability criteria. The analysis focuses on four key challenges: (1) the ambiguity of 'manner of manufacture' requirements for AI inventions lacking direct technical contributions to computing; (2) novel complexities in assessing the prior art and non-obviousness given AI's access to vast, opaque datasets; (3) the inadequacy of the 'person skilled in the art' standard for evaluating AI's inventive step; and (4) policy risks associated with lenient utility thresholds in an era of AI's prolific output. By critically analysing existing laws and precedents, the article contends that Australia's current patent regime is insufficient to address AI-driven inventions. It identifies that the human-centric nature of patent law should be preserved and proposes reforms to the Patents Act 1990 (Cth) to ensure that AI inventions are adequately captured under the patentability criteria, as well as procedural reforms to incorporate a multidisciplinary review process for evaluating technical advancements across disparate fields.
- Open Access
- 2 April 2026
- Published by Elsevier in SSRN Electronic Journal
Timing the Valve: How Does Intellectual Property Impact on Early Market Entry for mRNA Vaccines in Australia to Promote Vaccine Equity?
Much has been written about the potential for intellectual property to act as a barrier to access to medicines and vaccines for the most disadvantaged members of the global community (Tenni et al., 2022; Islam et al., 2019). The COVID experience provides a salutary lesson on the global failure to distribute vaccines equitably (Borges et al., 2022). The central focus of this chapter in on the need for improved vaccine equity, as defined by the US-based Centers for Disease Control: “when everyone, regardless of socioeconomic status, race, ethnicity, geographic location, or other determinants of health, has a fair and just opportunity to be vaccinated”. (Centres for Disease Control, 2024). We first discuss existing flexibilities in national and international intellectual property laws that may assist in alleviating concerns about lack of vaccine equity. We then consider the intellectual property landscape for a small group of relevant vaccines that serve as case studies for our analysis and assess whether any of the available flexibilities may be applicable. We explain in Part 1 that a number of relevant flexibilities exist in the Australian Patents Act 1990 (Cth) (Patents Act) which are compliant with international obligations. However, equivalent flexibilities do not exist for other forms of intellectual property, particularly the exclusivity that is provided by national agencies tasked with granting approvals for marketing of vaccine products for the use of clinical trials and other data submitted to them (which we refer to as hereafter regulatory data). This is problematic if it means that follow-on vaccine developers have to wait for expiry of the exclusivity period or undertake the costly and lengthy process of generating their own data. In Part 2, we ask the following question: when a first-in-class mRNA vaccine is provisionally or fully approved by the Australian Therapeutic Goods Administration (TGA) for inclusion on the Australian Register of Therapeutic Goods (ARTG), what actually determines the earliest lawful entry of a follow-on product? In addressing this question, we analyse patent and ARTG databases for the most commonly used platform technology for mRNA vaccine delivery to determine whether patents or regulatory data exclusivity create a binding “timing valve” for follow-on products. We then test whether any of the permissible flexibilities discussed in Part 1 could alleviate timing valve limitations. We conclude that it would be unwise to rely solely on these flexibilities and that other strategies will be needed to ensure that Australia can meet its obligations with regard to vaccine equity
- 2 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTiming the Valve: How Does Intellectual Property Impact on Early Market Entry for mRNA Vaccines in Australia to Promote Vaccine Equity?
Much has been written about the potential for intellectual property to act as a barrier to access to medicines and vaccines for the most disadvantaged members of the global community (Tenni et al., 2022; Islam et al., 2019). The COVID experience provides a salutary lesson on the global failure to distribute vaccines equitably (Borges et al., 2022). The central focus of this chapter in on the need for improved vaccine equity, as defined by the US-based Centers for Disease Control: “when everyone, regardless of socioeconomic status, race, ethnicity, geographic location, or other determinants of health, has a fair and just opportunity to be vaccinated”. (Centres for Disease Control, 2024). We first discuss existing flexibilities in national and international intellectual property laws that may assist in alleviating concerns about lack of vaccine equity. We then consider the intellectual property landscape for a small group of relevant vaccines that serve as case studies for our analysis and assess whether any of the available flexibilities may be applicable. We explain in Part 1 that a number of relevant flexibilities exist in the Australian Patents Act 1990 (Cth) (Patents Act) which are compliant with international obligations. However, equivalent flexibilities do not exist for other forms of intellectual property, particularly the exclusivity that is provided by national agencies tasked with granting approvals for marketing of vaccine products for the use of clinical trials and other data submitted to them (which we refer to as hereafter regulatory data). This is problematic if it means that follow-on vaccine developers have to wait for expiry of the exclusivity period or undertake the costly and lengthy process of generating their own data. In Part 2, we ask the following question: when a first-in-class mRNA vaccine is provisionally or fully approved by the Australian Therapeutic Goods Administration (TGA) for inclusion on the Australian Register of Therapeutic Goods (ARTG), what actually determines the earliest lawful entry of a follow-on product? In addressing this question, we analyse patent and ARTG databases for the most commonly used platform technology for mRNA vaccine delivery to determine whether patents or regulatory data exclusivity create a binding “timing valve” for follow-on products. We then test whether any of the permissible flexibilities discussed in Part 1 could alleviate timing valve limitations. We conclude that it would be unwise to rely solely on these flexibilities and that other strategies will be needed to ensure that Australia can meet its obligations with regard to vaccine equity
- 1 September 2023
- Published by Walter de Gruyter GmbH in Pólemos
- Vol. 17 (2) , 347-366
Non-singular Logics of Intellectual Property in Biomedical Innovation
The role of intellectual property in biomedical innovation is often construed by the source of its funding viz. public or private. While privately funded innovations are assumed to rely on intellectual property for monopolistic expansions and profit gains, publicly funded research is expected to serve the broader social good without proprietary constraints. In the light of the accumulating evidence over the last few decades, it is now understood that this causal narrative, appears simplistic. To gain a deeper understanding of innovation, whether profit-driven or socially oriented, it is crucial to examine the broader context of basic and translational research. This article investigates the management of intellectual property within two significant biomedical research funding organizations: the publicly funded United States National Institutes of Health (NIH) and the public-private-philanthropic partnership, the Coalition for Epidemic Preparedness Innovations (CEPI). The findings reveal that despite different claims about intellectual property strategies, these institutions exhibit similar practices influenced by the spectre of larger privatisation processes intrinsic to global market forces. This analysis suggests that a singular logic of one-size-fits-all approach to intellectual property is inadequate in promoting biomedical innovation for the greater public good.
- 1 September 2023
- Published by Walter de Gruyter GmbH in Pólemos
- Vol. 17 (2) , 347-366
Non-singular Logics of Intellectual Property in Biomedical Innovation
The role of intellectual property in biomedical innovation is often construed by the source of its funding viz. public or private. While privately funded innovations are assumed to rely on intellectual property for monopolistic expansions and profit gains, publicly funded research is expected to serve the broader social good without proprietary constraints. In the light of the accumulating evidence over the last few decades, it is now understood that this causal narrative, appears simplistic. To gain a deeper understanding of innovation, whether profit-driven or socially oriented, it is crucial to examine the broader context of basic and translational research. This article investigates the management of intellectual property within two significant biomedical research funding organizations: the publicly funded United States National Institutes of Health (NIH) and the public-private-philanthropic partnership, the Coalition for Epidemic Preparedness Innovations (CEPI). The findings reveal that despite different claims about intellectual property strategies, these institutions exhibit similar practices influenced by the spectre of larger privatisation processes intrinsic to global market forces. This analysis suggests that a singular logic of one-size-fits-all approach to intellectual property is inadequate in promoting biomedical innovation for the greater public good.
- Open Access
- 28 April 2023
- Published by Elsevier in SSRN Electronic Journal
The Impact of 3D Bioprinting Innovation on IP Ecosystem and Patent law: An Indian and US Perspective
Patenting issues related to emerging technologies has always caused turmoil in the innovation ecosystem since past few decades. Three-dimensional (3D) bioprinting is one of the emerging technologies that challenges the traditional patent systems around the globe due to the complexity of the subject matter related to bioprinting innovations. Traditional patent systems have historically been adapted to new technologies; however, the pace of technological advancement has always been faster. Given the complexity of bioprinting technology and the subject matter limitations in traditional patent systems, it is often challenging for patent applicants and inventors to obtain protection for their innovations, resulting in a detrimental affect on the IP ecosystem. This chapter addressed this issue by examining the patent provisions of India and the US in light of subject matter related to 3D bioprinted tissues and organs. The initial sections of this chapter analyses the patentable subject matter exclusions as defined in section 3 of the Patent Act 1970 and clarified by examination guidelines. The analysis of bioprinting innovations from a US perspective is provided in the chapter's later sections, that analysed the patentable subject matter provisions as defined by section 101 of US patent law, examination guidelines, and relevant case law.
- 28 April 2023
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Impact of 3D Bioprinting Innovation on IP Ecosystem and Patent law: An Indian and US Perspective
Patenting issues related to emerging technologies has always caused turmoil in the innovation ecosystem since past few decades. Three-dimensional (3D) bioprinting is one of the emerging technologies that challenges the traditional patent systems around the globe due to the complexity of the subject matter related to bioprinting innovations. Traditional patent systems have historically been adapted to new technologies; however, the pace of technological advancement has always been faster. Given the complexity of bioprinting technology and the subject matter limitations in traditional patent systems, it is often challenging for patent applicants and inventors to obtain protection for their innovations, resulting in a detrimental affect on the IP ecosystem. This chapter addressed this issue by examining the patent provisions of India and the US in light of subject matter related to 3D bioprinted tissues and organs. The initial sections of this chapter analyses the patentable subject matter exclusions as defined in section 3 of the Patent Act 1970 and clarified by examination guidelines. The analysis of bioprinting innovations from a US perspective is provided in the chapter's later sections, that analysed the patentable subject matter provisions as defined by section 101 of US patent law, examination guidelines, and relevant case law.
- 27 August 2018
- Published by thinkBiotech, LLC in Journal of Commercial Biotechnology
- Vol. 24 (2)
Patenting Bioinformatic Inventions: Global Perspective
Patenting bioinformatic inventions has become a ride on the rail to the scientists and inventors. Specifically in bioinformatics, drafting an invention in bounds of patentability criteria is one the most critical task for an inventor to protect his invention. As bioinformatics is a budding field of science, patentable subject matter in bioinformatics was not specifically defined by most of the patent offices in the world. In this regard, we have tried to explain patentable subject matter in bioinformatics by classifying bioinformatics into different subject fields. Additionally, we have tried to trace out patentable subject matter for bioinformatic inventions based on country-specific patentability standards and granted bioinformatic patents of US, Europe, India, Canada and Australia.
- 27 August 2018
- Published by thinkBiotech, LLC in Journal of Commercial Biotechnology
- Vol. 24 (2)
Patenting Bioinformatic Inventions: Global Perspective
Patenting bioinformatic inventions has become a ride on the rail to the scientists and inventors. Specifically in bioinformatics, drafting an invention in bounds of patentability criteria is one the most critical task for an inventor to protect his invention. As bioinformatics is a budding field of science, patentable subject matter in bioinformatics was not specifically defined by most of the patent offices in the world. In this regard, we have tried to explain patentable subject matter in bioinformatics by classifying bioinformatics into different subject fields. Additionally, we have tried to trace out patentable subject matter for bioinformatic inventions based on country-specific patentability standards and granted bioinformatic patents of US, Europe, India, Canada and Australia.
- 27 August 2018
- Published by thinkBiotech, LLC in Journal of Commercial Biotechnology
- Vol. 24 (2)
Patenting Therapeutic Methods: Statutes and Strategies
Patenting medical therapeutic methods has become one of the toughest tasks for inventors and scientists in some jurisdictions where these methods are excluded from patentable subject matter. There are recent amendments by different countries in relation to patentability aspects of Therapeutic methods. In this scenario, analysis of these recent amendments would provide a path for researchers in the field to identify whether their inventions are considered as patentable subject matter. Our analysis sheds some light on different statutes and regulations of major jurisdictions on the patentable subject matter and patentability aspects of therapeutic methods. Furthermore, we have identified that most of the jurisdictions restrict inventors in patenting therapeutic methods. However, some countries such as United States and Australia allow patents related to therapeutic methods. We think adapting different strategies that are provided in this article would help researchers, inventors and patent attorneys in patenting the inventions related to therapeutic methods. Moreover, while applying the provided strategies, it is suggested that inventors should draft the patent claims by keeping a note of different statutes and regulations of countries in which they are interested to file the patent applications.
- 27 August 2018
- Published by thinkBiotech, LLC in Journal of Commercial Biotechnology
- Vol. 24 (2)
Patenting Therapeutic Methods: Statutes and Strategies
Patenting medical therapeutic methods has become one of the toughest tasks for inventors and scientists in some jurisdictions where these methods are excluded from patentable subject matter. There are recent amendments by different countries in relation to patentability aspects of Therapeutic methods. In this scenario, analysis of these recent amendments would provide a path for researchers in the field to identify whether their inventions are considered as patentable subject matter. Our analysis sheds some light on different statutes and regulations of major jurisdictions on the patentable subject matter and patentability aspects of therapeutic methods. Furthermore, we have identified that most of the jurisdictions restrict inventors in patenting therapeutic methods. However, some countries such as United States and Australia allow patents related to therapeutic methods. We think adapting different strategies that are provided in this article would help researchers, inventors and patent attorneys in patenting the inventions related to therapeutic methods. Moreover, while applying the provided strategies, it is suggested that inventors should draft the patent claims by keeping a note of different statutes and regulations of countries in which they are interested to file the patent applications.
- Open Access
- 1 June 2017
- Published by Elsevier in Data in Brief
- Vol. 12, 150-155
Dataset of effect of Wogonin, a natural flavonoid, on the viability and activation of NF-κB and MAPKs in IL-1β-stimulated human OA chondrocytes
- 1 June 2017
- Published by Elsevier in Data in Brief
- Vol. 12, 150-155
Open AccessDataset of effect of Wogonin, a natural flavonoid, on the viability and activation of NF-κB and MAPKs in IL-1β-stimulated human OA chondrocytes
- Top Cited Papers
- 1 May 2017
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 106, 288-301
Wogonin, a plant derived small molecule, exerts potent anti-inflammatory and chondroprotective effects through the activation of ROS/ERK/Nrf2 signaling pathways in human Osteoarthritis chondrocytes
- 1 May 2017
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 106, 288-301
Top Cited PapersWogonin, a plant derived small molecule, exerts potent anti-inflammatory and chondroprotective effects through the activation of ROS/ERK/Nrf2 signaling pathways in human Osteoarthritis chondrocytes
- 16 January 2017
- Published by thinkBiotech, LLC in Journal of Commercial Biotechnology
- Vol. 22 (4)
Induced Pluripotent Stem Cells: Inventors turning into competitors
Induced Pluripotent Stem Cells (IPSCs) are a kind of adult cells that have been genetically reprogrammed to become different cell types. Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem cells. IPSCs technology was pioneered by Shinya Yamanaka from Kyoto University. This breakthrough has inspired researchers to start working around IPSC technology. James Thomson from University of California has developed IPS cell lines derived from Human Somatic Cells. Subsequently, he also established a large scale human IPSC manufacturing company named Cellular Dynamics International. Thus, increasing interest in the commercial exploitation of IPSCs patents has lead us to look into the patent portfolios of top three patent assignees in IPSC technology. In this study, we have discussed technological patent trends and multiple factors which reflect the competitive scenario between the top assignees of IPSC technology. Our conclusions suggest that Kyoto University led by inventor Shinya Yamanaka is the leader of IPSC technology. However, patent-product linkage analysis suggests that Cellular Dynamics International led by inventor James Thomson may surpass Kyoto University in near future.
- 16 January 2017
- Published by thinkBiotech, LLC in Journal of Commercial Biotechnology
- Vol. 22 (4)
Induced Pluripotent Stem Cells: Inventors turning into competitors
Induced Pluripotent Stem Cells (IPSCs) are a kind of adult cells that have been genetically reprogrammed to become different cell types. Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem cells. IPSCs technology was pioneered by Shinya Yamanaka from Kyoto University. This breakthrough has inspired researchers to start working around IPSC technology. James Thomson from University of California has developed IPS cell lines derived from Human Somatic Cells. Subsequently, he also established a large scale human IPSC manufacturing company named Cellular Dynamics International. Thus, increasing interest in the commercial exploitation of IPSCs patents has lead us to look into the patent portfolios of top three patent assignees in IPSC technology. In this study, we have discussed technological patent trends and multiple factors which reflect the competitive scenario between the top assignees of IPSC technology. Our conclusions suggest that Kyoto University led by inventor Shinya Yamanaka is the leader of IPSC technology. However, patent-product linkage analysis suggests that Cellular Dynamics International led by inventor James Thomson may surpass Kyoto University in near future.
- 13 July 2016
- Published by Wiley in Biofuels, Bioproducts and Biorefining
- Vol. 10 (5) , 534-541
Xylose utilization in ethanol production: a patent landscape
Bioethanol is considered as one of the best alternatives to fossil fuels as unwanted biomass is converted into fuel ethanol. As there is increasing demand for fuel ethanol, researchers have started looking for some better ways to produce ethanol. In light of the present scenario, we have attempted to develop a global patent landscape view of xylose utilization in ethanol production. Our country‐specific patent analysis has revealed that most of the research on xylose‐utilizing ethanol production is carried out in the USA followed by China and Sweden. Moreover, it has been found that more patent applications/grants have been claimed for processes, followed by recombinant strains. Patent publication trends for genes and enzymes have shown that most of the research is focused on the xylA gene and xylulokinase. Assignee patenting trends suggest that Du Pont is the major player in xylose‐utilizing ethanol production research. Additionally, analysis based on micro‐organisms used in xylose‐utilizing ethanol production revealed that most of the research has been performed using Saccharomyces cerevisiae to enhance the ethanol yields. © 2016 Society of Chemical Industry and John Wiley & Sons, Ltd
- 13 July 2016
- Published by Wiley in Biofuels, Bioproducts and Biorefining
- Vol. 10 (5) , 534-541
Xylose utilization in ethanol production: a patent landscape
Bioethanol is considered as one of the best alternatives to fossil fuels as unwanted biomass is converted into fuel ethanol. As there is increasing demand for fuel ethanol, researchers have started looking for some better ways to produce ethanol. In light of the present scenario, we have attempted to develop a global patent landscape view of xylose utilization in ethanol production. Our country‐specific patent analysis has revealed that most of the research on xylose‐utilizing ethanol production is carried out in the USA followed by China and Sweden. Moreover, it has been found that more patent applications/grants have been claimed for processes, followed by recombinant strains. Patent publication trends for genes and enzymes have shown that most of the research is focused on the xylA gene and xylulokinase. Assignee patenting trends suggest that Du Pont is the major player in xylose‐utilizing ethanol production research. Additionally, analysis based on micro‐organisms used in xylose‐utilizing ethanol production revealed that most of the research has been performed using Saccharomyces cerevisiae to enhance the ethanol yields. © 2016 Society of Chemical Industry and John Wiley & Sons, Ltd